Nektar Therapeutics (NKTR) Amortization of Deferred Charges (2012 - 2014)

Nektar Therapeutics' Amortization of Deferred Charges history runs 3 years deep, the most recent figure standing at $5.1 million for Q2 2014.

• On a quarterly basis, Amortization of Deferred Charges fell 6.4% year-over-year to $5.1 million in Q2 2014; TTM through Jun 2014 was $21.8 million, a 0.59% decrease from a year earlier, with the FY2013 full-year figure at $22.3 million, up 23.55% from the prior year.
• Amortization of Deferred Charges retreated to $5.1 million in Q2 2014 per NKTR's latest filing, from $5.4 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $5.7 million in Q4 2013 and bottomed at $1.8 million in Q1 2012.
• The 3-year median for Amortization of Deferred Charges is $5.5 million (2012), against an average of $5.1 million.
• Across the five-year window, Amortization of Deferred Charges soared 210.53% in 2013 and dropped 6.4% in 2014, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $5.4 million in 2012, then advanced by 4.6% to $5.7 million in 2013, then retreated by 9.37% to $5.1 million in 2014.
• Per Business Quant, the three latest NKTR Amortization of Deferred Charges figures stand at $5.1 million (Q2 2014), $5.4 million (Q1 2014), and $5.7 million (Q4 2013).